Zobrazeno 1 - 10
of 61
pro vyhledávání: '"A Strenge-Hesse"'
Autor:
Hernandez, R, Cooney, M, Dualé, C, Gálvez, M, Gaynor, S, Kardos, G, Kubiak, C, Mihaylov, S, Pleiner, J, Ruberto, G, Sanz, N, Skoog, M, Souri, P, Stiller, C O, Strenge-Hesse, A, Vas, A, Winter, D, Carné, X
Publikováno v:
Journal of Medical Ethics, 2009 Nov 01. 35(11), 696-700.
Externí odkaz:
https://www.jstor.org/stable/20696679
Autor:
Strenge-Hesse, Anke, Paulus, Ursula, Meyer, Sandra, Ihrig, Kristina, Houben, Peggy, Pfistner, Beate, Brosteanu, Oana, Ohmann, Christian, Zettelmeyer, Ulrike, Schwarz, Gabriele
Publikováno v:
GMS Medizinische Informatik, Biometrie und Epidemiologie, Vol 4, Iss 1, p Doc03 (2008)
For Investigator Initiated Trials (IITs) alternative risk-adapted monitoring strategies are discussed in order to fulfill rules and regulations, taking into consideration the restricted resources. In this systematic review investigations, presenting
Externí odkaz:
https://doaj.org/article/e25bc54fadd946afab2e5f0ce3befbad
Autor:
de Andres Fernando, Serrano Mariantonia, Schieppati Arrigo, Gaynor Siobhan, Cooney Margaret, O'Brien Timothy, Kardos Gabriella, Blasko Gyorgy, Temesvari Zsuza, Strenge-Hesse Anke, Kuchinke Wolfgang, Geismann Sebastian, Dreier Gabriele, Grählert Xina, Stankovski Lea, Kubiak Christine, Barraud Béatrice, Libersa Christian, Thirstrup Steffen, Winter Diana, Huemer Karl-Heinz, Whitfield Kate, Sanz Nuria, Hernández Raquel, Kreis Germán, Asker-Hagelberg Charlotte, Johansson Hanna, Asghar Adeeba, Husson Jean-Marc, Demotes Jacques, Gluud Christian
Publikováno v:
Trials, Vol 11, Iss 1, p 104 (2010)
Abstract Background 'Compassionate use' programmes allow medicinal products that are not authorised, but are in the development process, to be made available to patients with a severe disease who have no other satisfactory treatment available to them
Externí odkaz:
https://doaj.org/article/80d54c88429e4912aecac085f614a10b
Autor:
Anja Schneider, Anke Strenge-Hesse, Dirk Hasenclever, Peggy Houben, Ursula Paulus, Oana Brosteanu, Gabriele Schwarz, Ulrike Zettelmeyer
Publikováno v:
Clinical Trials (London, England)
Background According to Good Clinical Practice, clinical trials must protect rights and safety of patients and make sure that the trial results are valid and interpretable. Monitoring on-site has an important role in achieving these objectives; it co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64fe8e9565bc8a510d38eb7ecb781653
https://pubmed.ncbi.nlm.nih.gov/28786330
https://pubmed.ncbi.nlm.nih.gov/28786330
Autor:
Napp, Adriane E., Haase, Robert, Laule, Michael, Schuetz, Georg M., Rief, Matthias, Dreger, Henryk, Feuchtner, Gudrun, Friedrich, Guy, Spacek, Miloslav, Suchanek, Vojtech, Kofoed, Klaus Fuglsang, Engstroem, Thomas, Schroeder, Stephen, Drosch, Tanja, Gutberlet, Matthias, Woinke, Michael, Maurovich-Horvat, Pal, Merkely, Bela, Donnelly, Patrick, Ball, Peter, Dodd, Jonathan D., Quinn, Martin, Saba, Luca, Porcu, Maurizio, Francone, Marco, Mancone, Massimo, Erglis, Andrejs, Zvaigzne, Ligita, Jankauskas, Antanas, Sakalyte, Gintare, Haran, Tomasz, Ilnicka-Suckiel, Malgorzata, Bettencourt, Nuno, Gama-Ribeiro, Vasco, Condrea, Sebastian, Benedek, Imre, Adjic, Nada Cemerlic, Adjic, Oto, Rodriguez-Palomares, Jose, del Blanco, Bruno Garcia, Roditi, Giles, Berry, Colin, Davis, Gershan, Thwaite, Erica, Knuuti, Juhani, Pietila, Mikko, Kepka, Cezary, Kruk, Mariusz, Vidakovic, Radosav, Neskovic, Aleksandar N., Diez, Ignacio, Lecumberri, Inigo, Geleijns, Jacob, Kubiak, Christine, Strenge-Hesse, Anke, Do, The-Hoang, Fromel, Felix, Gutierrez-Ibarluzea, Inaki, Benguria-Arrate, Gaizka, Keiding, Hans, Katzer, Christoph, Mueller-Nordhorn, Jacqueline, Rieckmann, Nina, Walther, Mario, Schlattmann, Peter, Dewey, Marc, DISCHARGE Trial Grp
Publikováno v:
European Radiology
European Radiology, 27(7), 2957-2968
European Radiology, 27(7), 2957-2968
More than 3.5 million invasive coronary angiographies (ICA) are performed in Europe annually. Approximately 2 million of these invasive procedures might be reduced by noninvasive tests because no coronary intervention is performed. Computed tomograph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::953badfb157e43e6e6a565f9e7623447
https://vinar.vin.bg.ac.rs/handle/123456789/1603
https://vinar.vin.bg.ac.rs/handle/123456789/1603
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Dementia and Geriatric Cognitive Disorders. 10:181-185
Background: Silymarin is a well-known hepatoprotective agent. Tacrine, the first drug marketed for Alzheimer’s disease (AD), induces an elevation of serum liver transaminase prohibiting an effective dosage in many patients. This 12-week randomised,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02dfe6c28c3031ba1d800bff90cf8ab6
https://doi.org/10.1159/000017117
https://doi.org/10.1159/000017117
Autor:
Gabriella Kardos, Xina Grählert, Margaret Cooney, Raquel Hernandez, György Blaskó, Anke Strenge-Hesse, Mariantonia Serrano, Wolfgang Kuchinke, Timothy O'Brien, Christine Kubiak, Fernando de Andres, Arrigo Schieppati, Christian Gluud, Jacques Demotes, Jean-Marc Husson, Hanna Johansson, Diana Winter, Siobhan Gaynor, Nuria Sanz, Steffen Thirstrup, Béatrice Barraud, German Kreis, Sebastian Geismann, Kate Whitfield, Charlotte Asker-Hagelberg, Lea Stankovski, Christian Libersa, Gabriele Dreier, Adeeba Asghar, Zsuza Temesvari, Karl-Heinz Huemer
Publikováno v:
Trials
Trials, BioMed Central, 2010, 11 (1), pp.104. ⟨10.1186/1745-6215-11-104⟩
Trials, Vol 11, Iss 1, p 104 (2010)
Trials, BioMed Central, 2010, 11 (1), pp.104. ⟨10.1186/1745-6215-11-104⟩
Trials, Vol 11, Iss 1, p 104 (2010)
Background 'Compassionate use' programmes allow medicinal products that are not authorised, but are in the development process, to be made available to patients with a severe disease who have no other satisfactory treatment available to them. We soug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41797ac93026cc092a607f64abde60a0
Autor:
G Ruberto, X Carné, M Gálvez, R Hernandez, C Dualé, P Souri, Gabriella Kardos, N. Sanz, A Strenge-Hesse, C O Stiller, J Pleiner, S Gaynor, Christine Kubiak, M Skoog, M Cooney, D Winter, S Mihaylov, A Vas
Publikováno v:
Journal of medical ethics. 35(11)
Background: The Directive 2001/20/EC was an important first step towards consistency in the requirements and processes for clinical trials across Europe. However, by applying the same rules to all types of drug trials and transposing the Directive’
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b0fb7b2626731b03b54d4afa8569c18
https://pubmed.ncbi.nlm.nih.gov/19880708
https://pubmed.ncbi.nlm.nih.gov/19880708